Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Non Operating Income (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Non Operating Income for 9 consecutive years, with $1.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Non Operating Income rose 79.32% year-over-year to $1.8 million, compared with a TTM value of $4.1 million through Jun 2025, up 36.88%, and an annual FY2025 reading of $3.0 million, down 21.31% over the prior year.
  • Non Operating Income was $1.8 million for Q2 2025 at VYNE Therapeutics, up from $594000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.8 million in Q2 2025 and bottomed at -$69000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $435388.9, with a median of $249500.0 recorded in 2022.
  • The sharpest move saw Non Operating Income crashed 112.59% in 2021, then skyrocketed 8866.67% in 2023.
  • Year by year, Non Operating Income stood at $26000.0 in 2021, then surged by 807.69% to $236000.0 in 2022, then soared by 188.14% to $680000.0 in 2023, then rose by 11.76% to $760000.0 in 2024, then surged by 136.18% to $1.8 million in 2025.
  • Business Quant data shows Non Operating Income for VYNE at $1.8 million in Q2 2025, $594000.0 in Q1 2025, and $760000.0 in Q4 2024.